First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-06-11
DOI
10.1038/s41416-020-0916-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)—validation in two independent cohorts
- (2018) Ida Kappel Buhl et al. PLoS One
- Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study
- (2018) Anna Sofie Kappel Buhl et al. BREAST CANCER RESEARCH AND TREATMENT
- RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model
- (2018) Anna Mizutani et al. CANCER SCIENCE
- Combining PARP inhibition, radiation, and immunotherapy: A possible strategy to improve the treatment of cancer?
- (2018) Mathieu Césaire et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Poly(ADP-ribose) polymerase activity and inhibition in cancer
- (2017) Caleb Dulaney et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- PARP inhibitors in ovarian cancer: evidence, experience and clinical potential
- (2017) Tarra Evans et al. Therapeutic Advances in Medical Oncology
- PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
- (2016) G E Konecny et al. BRITISH JOURNAL OF CANCER
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study
- (2015) Robert L. Coleman et al. GYNECOLOGIC ONCOLOGY
- Poly(ADP-ribosyl)ation of FOXP3 Protein Mediated by PARP-1 Protein Regulates the Function of Regulatory T Cells
- (2015) Xuerui Luo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- PARP-2 domain requirements for DNA damage-dependent activation and localization to sites of DNA damage
- (2015) Amanda A. Riccio et al. NUCLEIC ACIDS RESEARCH
- E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling
- (2015) Sharon McGonigle et al. Oncotarget
- Poly(ADP-ribose) polymerase-1 inhibitor modulates T regulatory and IL-17 cells in the prevention of adjuvant induced arthritis in mice model
- (2014) Sheikh Fayaz Ahmad et al. CYTOKINE
- Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy
- (2013) Wei Liao et al. IMMUNITY
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
- (2013) J. Murai et al. MOLECULAR CANCER THERAPEUTICS
- PARP-1 Controls Immunosuppressive Function of Regulatory T Cells by Destabilizing Foxp3
- (2013) Pin Zhang et al. PLoS One
- Role of PARP Inhibitors in Cancer Biology and Therapy
- (2012) D. Davar et al. CURRENT MEDICINAL CHEMISTRY
- Homogeneous Datasets of Triple Negative Breast Cancers Enable the Identification of Novel Prognostic and Predictive Signatures
- (2011) Thomas Karn et al. PLoS One
- Increased Foxp3+ Regulatory T Cells in Poly(ADP-Ribose) Polymerase-1 Deficiency
- (2010) F. Nasta et al. JOURNAL OF IMMUNOLOGY
- Poly(ADP-ribose) polymerase-1 modulates interferon-γ-inducible protein (IP)-10 expression in murine embryonic fibroblasts by stabilizing IP-10 mRNA
- (2010) Marisa Galbis-Martínez et al. MOLECULAR IMMUNOLOGY
- Influence of Serum and Soluble CD25 (sCD25) on Regulatory and Effector T-cell Function in Hepatocellular Carcinoma
- (2010) R. Cabrera et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- The potential role and application of PARP inhibitors in cancer treatment
- (2009) A. J. Chalmers BRITISH MEDICAL BULLETIN
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started